
Dr. Dietrich Stephan: New Drugs that Repair Broken Genes
Talking Biotech with Dr. Kevin Folta
00:00
Cancer Driving Proteins - What's Next?
There are no therapeutic solutions to address this activated cogen. The oncogene is called cras, kr a s and the two most prevalent mutations in cras are called g 12 d and g 12 v is in victor. And they're among the most deadly because no one has developed any drugs that target these activated oncogens or their resultant proteins. So it plays to the sweet spot of our technology. We can put a lock right on top of the mutation,. On top of the point muta, and inhibit our eplimeras from forming amu mrna, or a cancer driving protein.
Transcript
Play full episode